Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon.
Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive.
Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 34.6K |
| Three Month Average Volume | 999.5K |
| High Low | |
| Fifty-Two Week High | 8.4 USD |
| Fifty-Two Week Low | 3.05 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 09 Jul 2024 |
| Price and Volume | |
| Current Price | 3.58 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.07% |
| Thirteen Week Relative Price Change | -32.01% |
| Twenty-Six Week Relative Price Change | -50.66% |
| Fifty-Two Week Relative Price Change | -65.21% |
| Year-to-Date Relative Price Change | -18.47% |
| Price Change | |
| One Day Price Change | 0.85% |
| Thirteen Week Price Change | -27.24% |
| Twenty-Six Week Price Change | -45.75% |
| Five Day Price Change | 0.85% |
| Fifty-Two Week Price Change | -56.40% |
| Year-to-Date Price Change | -3.45% |
| Month-to-Date Price Change | 4.53% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.6059 USD |
| Book Value Per Share (Most Recent Quarter) | 0.31259 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.6059 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.31259 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.39113 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.38596 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.35792 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.14589 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.07042 USD |
| Normalized (Last Fiscal Year) | -4.14589 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.14589 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.05865 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.14589 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.07042 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.2575 USD |
| Cash Per Share (Most Recent Quarter) | 1.9207 USD |
| Cash Flow Per Share (Last Fiscal Year) | -4.14061 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.90196 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.38434 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -976 |
| Cash Flow Revenue (Trailing Twelve Months) | -387 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -253.60% |
| Pretax Margin (Last Fiscal Year) | -1,074.17% |
| Pretax Margin (5 Year) | -1,104.55% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | 0.85% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,101.89% |
| Operating Margin (Trailing Twelve Months) | -231.38% |
| Operating Margin (5 Year) | -1,114.71% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,074.17% |
| Net Profit Margin (Trailing Twelve Months) | -253.60% |
| Net Profit Margin (5 Year) | -1,104.55% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 121.37% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 225.16% |
| EPS Change (Trailing Twelve Months) | 81.16% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | 11 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -16,414,990 |
| Net Debt (Last Fiscal Year) | -10,476,060 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11 |
| Price to Sales (Trailing Twelve Months) | 11 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | 11 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -39,486,080 |
| Free Cash Flow (Trailing Twelve Months) | -10,982,960 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -92.65% |
| Return on Assets (Trailing Twelve Months) | -30.76% |
| Return on Assets (5 Year) | -109.51% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -994.69% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -284.56% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -463.87% |
| Return on Investment (Trailing Twelve Months) | -191.39% |
| Return on Investment (5 Year) | -246.26% |